BUZZ-Viridian rises on plans to begin late-stage trials for eye disorder drug

Reuters06-11

** Shares of Viridian Therapeutics rise 6.4% to $13 premarket

** Co plans to begin two late-stage studies testing its experimental drug to treat patients with moderate-to-severe thyroid eye disease (TED) in August

** Data from the studies expected in the first half of 2026

** TED is an autoimmune eye disorder that causes inflammation and damage to tissues around the eye

** VRDN plans to file for marketing approval for the drug, VRDN-003, by end-2026

** VRDN-003 is administered as an under-the-skin injection with dosing as infrequently as every 8 weeks for a total of 3 administrations - VRDN

** Stifel analyst Alex Thompson says VRDN-003 could be the "best-in-class subcutaneous program" for TED

** Up to last close, stock down ~44% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment